LIF (human, recombinant)

Differentiation Inhibitory Factor|HILDA|Human Interleukin in DA Cells|Leukemia Inhibitor Factor|LIF Interleukin 6 Family Cytokine|Melanoma-derived LPL Inhibitor|MLPLI

Leukemia inhibitory factor (LIF) is a cytokine and member of the IL-6 family with roles in cell growth and differentiation, bone metabolism, and inflammation.{52602} Mature LIF is a 180-amino acid peptide arranged as a four-helix bundle in an up-up-down-down configuration that is synthesized as a 202-amino acid precursor which is post-translationally processed to remove a 22-amino acid signaling sequence from its N-terminus. It is ubiquitously expressed and this expression is commonly upregulated under inflammatory conditions.{52603} LIF binds to its receptor LIFRβ and recruits the IL-6 family common receptor gp130 to form a heterodimer and induce intracellular signaling via the JAK-STAT pathway.{52602,52604} Exogenous administration of LIF reduces the rate of deterioration in grip strength and slows progression of the forelimb deformity in the wobbler mouse model of amyotrophic lateral sclerosis (ALS).{52605} Intracerebroventricular administration of a recombinant adeno-associated viral vector encoding LIF reduces food intake and body weight gain in rats.{52606} Knockdown of Lif induces infertility in female mice.{52602} Cayman’s LIF (human, recombinant) protein can be used for cell-based assay applications. This protein consists of 180 amino acids, has a calculated molecular weight of 19.7 kDa, and a predicted N-terminus of Ser23 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 35.4 kDa due to glycosylation.

-80

-80

Lyophilized from sterile PBS, pH 7.4

365

≥95% estimated by SDS-PAGE